ATE120235T1 - Suppression von zell-proliferation durch decorin. - Google Patents

Suppression von zell-proliferation durch decorin.

Info

Publication number
ATE120235T1
ATE120235T1 AT89730152T AT89730152T ATE120235T1 AT E120235 T1 ATE120235 T1 AT E120235T1 AT 89730152 T AT89730152 T AT 89730152T AT 89730152 T AT89730152 T AT 89730152T AT E120235 T1 ATE120235 T1 AT E120235T1
Authority
AT
Austria
Prior art keywords
decorin
cell proliferation
suppression
suppress
proliferation
Prior art date
Application number
AT89730152T
Other languages
English (en)
Inventor
Erkki I Ruoslahti
Yu Yamaguchi
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Application granted granted Critical
Publication of ATE120235T1 publication Critical patent/ATE120235T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
AT89730152T 1988-06-28 1989-06-24 Suppression von zell-proliferation durch decorin. ATE120235T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21270288A 1988-06-28 1988-06-28

Publications (1)

Publication Number Publication Date
ATE120235T1 true ATE120235T1 (de) 1995-04-15

Family

ID=22792114

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89730152T ATE120235T1 (de) 1988-06-28 1989-06-24 Suppression von zell-proliferation durch decorin.

Country Status (11)

Country Link
US (2) US5726149A (de)
EP (1) EP0349480B1 (de)
JP (3) JP2887325B2 (de)
AT (1) ATE120235T1 (de)
AU (1) AU633011B2 (de)
CA (1) CA1340112C (de)
DE (1) DE68921803T2 (de)
DK (1) DK306890D0 (de)
ES (1) ES2070926T3 (de)
FI (1) FI906411A0 (de)
WO (1) WO1990000194A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583103A (en) * 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
US6509314B1 (en) * 1988-06-28 2003-01-21 The Burnham Institute Methods of preventing or reducing scarring with decorin or biglycan
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
EP0667784B1 (de) * 1991-11-14 2003-03-05 La Jolla Cancer Research Foundation Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildung
US5830847A (en) * 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US5650389A (en) * 1993-03-01 1997-07-22 University Of Alabama At Birmingham Research Foundation Methods for the inhibition of complement activation
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5567807A (en) * 1994-07-08 1996-10-22 La Jolla Cancer Research Foundation Processes for the purification of human recombinant decorin and the detection of guanidinium ions
JP2001520877A (ja) 1997-10-28 2001-11-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 血管平滑筋細胞のインビトロ分化、それに関する方法および試薬
NZ522971A (en) * 2000-05-05 2005-02-25 Gtc Biotherapeutics Inc Transgenically produced decorin in the mammary gland of a transgenic animal
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
JP4564261B2 (ja) * 2002-01-22 2010-10-20 ジェンザイム、コーポレーション 慢性的移植片拒絶反応の治療と予防のためのＴＧＦ−β拮抗薬の使用
NZ550217A (en) * 2004-03-31 2009-11-27 Genentech Inc Humanized anti-TGF-beta antibodies
EP1809324A4 (de) * 2004-10-13 2009-02-25 Univ Ohio State Res Found Verfahren zur behandlung oder prävention von viralen lymphoproliferativen erkrankungen
KR100747646B1 (ko) * 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
JP2006295872A (ja) * 2005-03-18 2006-10-26 Matsushita Electric Ind Co Ltd 機器固有鍵の生成方法、これを用いた機密情報処理機能を備えた機密情報ｌｓｉ、これを搭載したホスト機器、これに用いられる認証機能付き記録媒体、および認証機能を備えた記録媒体付き携帯端末
CN101277960A (zh) 2005-09-29 2008-10-01 默克公司 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
EP2862867A3 (de) 2005-10-25 2015-08-05 The Johns Hopkins University Verfahren und Zusammensetzungen zur Behandlung des Marfan-Syndroms und assoziierter Erkrankungen
EP1998810A4 (de) 2006-03-13 2009-09-02 Univ Johns Hopkins Erhöhung der endothelialen thromboresistenz
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
PL2083863T3 (pl) * 2006-10-03 2015-08-31 Genzyme Corp Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej
US9053063B2 (en) 2007-02-21 2015-06-09 At&T Intellectual Property I, Lp Method and apparatus for authenticating a communication device
EP2145884B1 (de) 2007-04-02 2014-08-06 Msd K.K. Indoledionderivat
HUE027831T2 (en) 2010-03-12 2016-11-28 Genzyme Corp Combination therapy for breast cancer
EP2660314A4 (de) 2010-12-27 2014-09-03 Lsip Llc Ips-zellen und verfahren zu ihrer erzeugung
US20120238727A1 (en) * 2011-03-14 2012-09-20 Catalent Pharma Solutions Llc Decorin compositions and use thereof
EP2737083A1 (de) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Verfahren zur diagnose und behandlung des myhre-syndroms
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
WO2013100208A1 (ja) 2011-12-28 2013-07-04 京都府公立大学法人 角膜内皮細胞の培養正常化
WO2014176198A1 (en) 2013-04-22 2014-10-30 Catalent Pharma Solutions, Llc Veterinary decorin compositions and use thereof
WO2015064768A1 (ja) 2013-10-31 2015-05-07 京都府公立大学法人 角膜内皮の小胞体細胞死関連疾患治療薬
WO2016187312A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU624789B2 (en) * 1987-02-19 1992-06-25 Amgen, Inc. Purified platelet-derived growth factor and methods for purification thereof
US5583103A (en) * 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity

Also Published As

Publication number Publication date
AU3865389A (en) 1990-01-23
EP0349480B1 (de) 1995-03-22
DK306890A (da) 1990-12-28
JP2887325B2 (ja) 1999-04-26
ES2070926T3 (es) 1995-06-16
JPH09117278A (ja) 1997-05-06
DK306890D0 (da) 1990-12-28
JP2003034651A (ja) 2003-02-07
CA1340112C (en) 1998-11-03
AU633011B2 (en) 1993-01-21
JPH03503846A (ja) 1991-08-29
EP0349480A1 (de) 1990-01-03
US6046162A (en) 2000-04-04
US5726149A (en) 1998-03-10
DE68921803T2 (de) 1995-07-13
WO1990000194A1 (en) 1990-01-11
FI906411A0 (fi) 1990-12-27
DE68921803D1 (de) 1995-04-27

Similar Documents

Publication Publication Date Title
ATE120235T1 (de) Suppression von zell-proliferation durch decorin.
EP0123811A3 (en) The use of the gal 1 yeast promoter
GR3035603T3 (en) Mammals lacking expression of cd28 transgenic
DE69032406D1 (de) Wundheilmittel enthaltend heparanase
EP0193926A3 (en) Phenyl carbamates
ES2036192T3 (es) Derivados del acido (met)-acrilico, que contienen grupos uretano, de triciclo (5.2.1.0.2.6) decano.
WO1989001515A3 (en) Plants transformed with a dna sequence from bacillus thuringiensis
AU1621783A (en) Cell culture microcarriers
ES2000510A6 (es) Procedimiento para la obtencion del enzima rldm tm degradantes de lignina.
DK359487D0 (da) Fremgangsmaade til udvirkning af foroeget ekspression af rekombinant faktor viii i en vaertscelle
HUT44540A (en) Process for preparing monosulfactams
AU586330B2 (en) Process for maximum middle distillate production with minimum hydrogen consumption
DE3782271T2 (de) Verwendung von geladenen partikeln in der membranfiltration von fluessigen zellkulturmedien.
NO905610L (no) Undertrykkelse av celleproliferasjon ved hjelp av decorin.
AU6918881A (en) Test kit to identify potential contrast media reactors
EP0193883A3 (en) Well forming apparatus
DE3481778D1 (de) Verwendung von vernetzerkombinationen enthaltende polyurethanzubereitungen als thermoaktive haftstriche.
ES8401255A1 (es) Metodo para la determinacion colorimetrica de peroxidos.
CA2133345A1 (en) A Method of Limiting the Survival of Genetically Engineered Microorganisms in Their Environment
AU524884B2 (en) Refining high carbon steel
AU561330B2 (en) Liquefaction of coal with hydrogen
KR910012253A (ko) 폴리-3-히드록시부티르산의 생합성 방법
IT220635Z2 (it) Impianto autorigeneratore con cella elettrolitica per la produzione di idrogeno e di ossigeno in sostituzione dei prodotti petroliferi.
ATE167515T1 (de) Kulturgefäss für zellkulturen
ZA846919B (en) Genetically engineered microorganism for the massive production of alpha amylase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee